A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

A Phase II Trial of Amphotericin B Oral Suspension for Fluconazole-Resistant Oral Candidiasis in HIV-Infected Patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00001065

Enrollment

Registered

2001-08-31

Start date

Unknown

Completion date

1998-04-30

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Candidiasis, Oral, HIV Infections

Keywords

Administration, Oral, Acquired Immunodeficiency Syndrome, Amphotericin B, AIDS-Related Complex, Candidiasis, Oral, Suspensions

Brief summary

To assess response and toxicity in patients with fluconazole-resistant oral candidiasis ( thrush ) when given initial induction with amphotericin B oral suspension. Experience with amphotericin B oral suspension for drug-sensitive thrush in HIV-infected patients is limited but encouraging.

Detailed description

Experience with amphotericin B oral suspension for drug-sensitive thrush in HIV-infected patients is limited but encouraging. Patients swish and swallow amphotericin B oral suspension after each meal and at bedtime for 14 days, at which time they are deemed a responder, nonresponder, or failure to induction therapy. Responders receive maintenance twice daily, while nonresponders receive 14 further days of initial induction. Failures discontinue the study. Responders after 28 days of induction are placed on maintenance. After successful completion of initial induction, patients remain on study for 6 months.

Interventions

DRUGAmphotericin B

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

13 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients must have: * HIV infection OR diagnosis of AIDS. * Diffuse oral candidiasis, symptomatic or asymptomatic, that is resistant to fluconazole.

Exclusion criteria

Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Current symptoms of esophageal candidiasis unless there are negative endoscopic visualization and biopsy for Candida or related yeasts. * Perioral lesions only (e.g., angular stomatitis, perleche). * Inability to swish and swallow oral solution. * Inability to tolerate further oral therapy for thrush. Concurrent Medication: Excluded: * Fluconazole. * Itraconazole. * Ketoconazole. * Flucytosine. * Intravenous amphotericin or other non-study formulations. * Nystatin. * Clotrimazole. * Other investigational antifungal agents. * Systemic cytotoxic chemotherapy for malignancy. Concurrent Treatment: Excluded: * Radiation therapy to the mouth, neck, or chest. Patients with the following prior conditions are excluded: * Esophageal candidiasis, proven or presumptive, occurring since fluconazole failure. * Successful treatment of thrush with fluconazole at \<= 200 mg/day after original treatment failure. * History of oral candidiasis that recurred or persisted despite IV amphotericin B given once or more weekly. * History of anaphylaxis to amphotericin B. * History of hypersensitivity to components in amphotericin B oral suspension. Prior Medication: Excluded within 6 weeks prior to study entry: * Cytotoxic therapy for malignancy. * Corticosteroids at higher than replacement doses.

Countries

Puerto Rico, Tanzania, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026